Marker for inflammatory conditions

• US 6,699,675 B2
• Filed: 07/31/2002
• Issued: 03/02/2004
• Est. Priority Date: 01/12/2001
• Status: Expired due to Term

• Current Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Original Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Inventors: Holmes, David R., Schwartz, Robert S.
• Primary Examiner(s): Le, Long V.
• Assistant Examiner(s): Davis, Deborah A
• Application Number:
  US10/210,339
• Publication Number:
  US 20030003521A1
• Time in Patent Office: 580 Days
• Field of Search: 435/7.1, 435/7.92, 435/7.94, 435/7.5, 436/518, 436/501, 530/387.9, 424/1.85, 424/1.11
• US Class Current: 435/7.1
• CPC Class Codes: C07K 14/4715 Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
• CPC Class Codes: G01N 2800/324 Coronary artery diseases, e.g. angina pectoris, myocardial infarction
• CPC Class Codes: G01N 2800/368 Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
• CPC Class Codes: G01N 33/5091 for testing the pathological state of an organism
• CPC Class Codes: G01N 33/564 for pre-existing immune complex or autoimmune disease , i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
• CPC Class Codes: G01N 33/689 related to pregnancy or the gonads
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

Use of pregnancy-associated plasma protein-A as a marker for inflammatory conditions, and in particular, for acute coronary syndromes is described.

Claims

1. A method for diagnosing an acute coronary syndrome, said method comprising:

a) administering to a patient an amount of an antibody having specific binding affinity for pregnancy-associated plasma protein-A (PAPP-A) effective to detectably bind to PAPP-A, wherein said antibody is labeled;

b) detecting the level of said antibody bound to PAPP-A in said patient; and

c) diagnosing said acute coronary syndrome based on the level of said antibody bound to PAPP-A in said patient.

2. The method of claim 1, wherein said detecting step comprises diagnostic imaging.

3. The method of claim 2, wherein said diagnostic imaging comprises positron emission tomography, gamma-scintigraphy, single photon emission computerized tomography, magnetic resonance imaging, intravascular ultrasound, or functional magnetic resonance imaging.

4. The method of claim 1, wherein said label is a radioisotope.

5. The method of claim 4, wherein said radioisotope is selected from the group consisting of ¹²³I, ¹⁸F, ¹¹¹In, ⁶⁷Ga, and ⁹⁹mTc.

6. The method of claim 1, wherein said antibody is administered intravenously.

7. The method of claim 1, wherein said acute coronary syndrome is selected from the group consisting of unstable angina, acute myocardial infarction, sudden cardiac death, coronary plaque rupture, and thrombosis.

8. The method of claim 1, wherein said acute coronary syndrome is unstable angina.

9. The method of claim 1, wherein said acute coronary syndrome is acute myocardial infarction.